LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 4, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO): Fiscal Year 2024 Third Quarter Highlights Completed the sale of its PICC and Midline product portfolios to Spectrum Vascular on February 15, 2024 Discontinued its Uniblate and Starburst RadioFrequency products, as

New Indication for Treatment of Pulmonary Embolism Enhances Device Utility in Critical Medical Scenarios LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 4, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s

LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 1, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced

LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 19, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today

LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 6, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced

Portfolio optimization enhances strategic focus and follows initiative to restructure manufacturing footprint Company to discontinue sales of radiofrequency ablation and Syntrax products LATHAM, N.Y. --(BUSINESS WIRE)--Feb. 15, 2024-- AngioDynamics, Inc.

225-cm Catheter Length Expands Access Points in Atherectomy Procedures to Help Reduce Access Site Complications and Accelerate Patient Recovery LATHAM, N.Y. --(BUSINESS WIRE)--Jan. 23, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on

Fiscal Year 2024 Second Quarter Highlights Net sales of $79.1 million increased 2.7% on a pro-forma basis compared to the prior-year quarter Med Tech net sales of $25.4 million increased 3.5% Med Device net sales of $53.7 million increased 2.3% on a pro-forma basis Gross margin of 50.9% declined 80

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 21, 2023-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 7, 2023-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today

122 Patients Enrolled in Single-arm IDE Study; 30-Day Follow-up LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 7, 2023-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer

  Fiscal Year 2024 First Quarter Highlights Net sales of $78.7 million as reported Includes $0.7 million of Dialysis and BioSentry Biopsy Tract Sealant System sales Net sales increased 5.7% on a pro-forma basis when excluding Dialysis and BioSentry, compared to the prior-year quarter Med Tech net

LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 12, 2023-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today

Pivotal Milestone Accelerates Pathway to Specific Indication LATHAM, N.Y. --(BUSINESS WIRE)--Aug. 15, 2023-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment

Pivotal Study of NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population LATHAM, N.Y. --(BUSINESS WIRE)--Aug. 3, 2023-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the

LATHAM, N.Y. --(BUSINESS WIRE)--Jul. 31, 2023-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today

LATHAM, N.Y. --(BUSINESS WIRE)--Jul. 24, 2023-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today

Fiscal Year 2023 Fourth Quarter Highlights Net sales of $91.1 million increased 4.7% compared to the prior-year quarter Med Tech net sales of $26.5 million increased 17.2% Med Device net sales of $64.6 million increased 0.3% Gross margin of 50.9% declined 250 basis points year over year GAAP loss

LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 20, 2023-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today

Announces preliminary Fiscal Year 2023 net sales in the range of $338 million to $339 million LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 8, 2023-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular